Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units

被引:8
作者
Love, Sharon B. [1 ]
Cafferty, Fay [2 ]
Snowdon, Claire [2 ]
Carty, Karen [3 ]
Savage, Joshua [4 ]
Pallmann, Philip [5 ]
McParland, Lucy [6 ]
Brown, Louise [1 ]
Masters, Lindsey [1 ]
Schiavone, Francesca [1 ]
Hague, Dominic [1 ]
Townsend, Stephen [1 ]
Amos, Claire [1 ]
South, Annabelle [1 ]
Sturgeon, Kate [1 ]
Langley, Ruth [1 ]
Maughan, Timothy [7 ]
James, Nicholas [2 ]
Hall, Emma [2 ]
Kernaghan, Sarah [2 ]
Bliss, Judith [2 ]
Turner, Nick [2 ]
Tutt, Andrew [8 ]
Yap, Christina [2 ,9 ]
Firth, Charlotte [9 ]
Kong, Anthony [10 ]
Mehanna, Hisham [11 ]
Watts, Colin [12 ]
Hills, Robert [13 ]
Thomas, Ian [14 ]
Copland, Mhairi [15 ]
Bell, Sue [16 ]
Sebag-Montefiore, David [17 ]
Jones, Robert [18 ]
Parmar, Mahesh K. B. [1 ]
Sydes, Matthew R. [1 ]
机构
[1] MRC Clin Trials Unit UCL, 90 High Holborn, London WC1V 6LJ, England
[2] Inst Canc Res, London SW7 3RP, England
[3] Canc Res UK Clin Trials Unit, Level 0 Beatson West Scotland Canc Ctr, Glasgow G12 0YN, Lanark, Scotland
[4] Univ Birmingham, Inst Canc & Genom Sci, Canc Res UK Clin Trials Unit CRCTU, Birmingham B15 2TT, W Midlands, England
[5] Cardiff Univ, Ctr Trials Res, Heath Pk, Cardiff CF14 4YS, Wales
[6] PHASTAR, Bollo Lane, London W4 5LE, England
[7] Univ Oxford, Oxford OX3 7DQ, England
[8] Inst Canc Res, London SW3 6JB, England
[9] Univ Birmingham, Coll Med & Dent Sci, Inst Canc & Genom Sci, Canc Res UK Clin Trials Unit, Birmingham B15 2TT, W Midlands, England
[10] Kings Coll London, Comprehens Canc Ctr, Guys Campus,New Hunts House,Room 2-36b, London SE1 1UL, England
[11] Univ Birmingham, Inst Head & Neck Studies & Educ, Birmingham B15 2TT, W Midlands, England
[12] Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England
[13] Univ Oxford, Nuffield Dept Populat Hlth, CTSU, Doll Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England
[14] Cardiff Univ, Ctr Trials Res, Heath Pk Way, Cardiff CF14 4YS, Wales
[15] Gartnavel Royal Hosp, Paul OGorman Res Ctr, Glasgow G12 0YN, Lanark, Scotland
[16] Univ Leeds, Leeds Inst Clin Trials Res, Clin Trials Res Unit CTRU, Leeds LS2 9JT, W Yorkshire, England
[17] St James Inst Oncol, Level 4 Bexley Wing, Leeds LS9 7TF, W Yorkshire, England
[18] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
关键词
Platform protocols; Trial conduct; Multi-arm multi-stage trials; Umbrella trials; Basket trials; Stratified medicine; Complex innovative designs; Methodology; MULTIARM;
D O I
10.1186/s13063-022-06680-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively used. We have gathered the experience of running a number of successful platform protocols together to present some operational recommendations. Methods Representatives of six UK clinical trials units with experience in running late-phase platform protocols attended a 1-day meeting structured to discuss various practical aspects of running these trials. We report and give guidance on operational aspects which are either harder to implement compared to a traditional late-phase trial or are specific to platform protocols. Results We present a list of practical recommendations for trialists intending to design and conduct late-phase platform protocols. Our recommendations cover the entire life cycle of a platform trial: from protocol development, obtaining funding, and trial set-up, to a wide range of operational and regulatory aspects such as staffing, oversight, data handling, and data management, to the reporting of results, with a particular focus on communication with trial participants and stakeholders as well as public and patient involvement. Discussion Platform protocols enable many questions to be answered efficiently to the benefit of patients. Our practical lessons from running platform trials will support trial teams in learning how to run these trials more effectively and efficiently.
引用
收藏
页数:14
相关论文
共 36 条
  • [1] [Anonymous], ACTIV 3 THERAPEUTICS
  • [2] [Anonymous], PRINCIPLE PLATFORM R
  • [3] [Anonymous], REV PLATFORM PROTOCO
  • [4] [Anonymous], RECOVERY (Randomised Evaluation of COVID-19 Therapy) Trial
  • [5] Beckman R.A., 2019, PLATFORM TRIALS DRUG
  • [6] Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement
    Blagden, Sarah P.
    Billingham, Lucinda
    Brown, Louise C.
    Buckland, Sean W.
    Cooper, Alison M.
    Ellis, Stephanie
    Fisher, Wendy
    Hughes, Helen
    Keatley, Debbie A.
    Maignen, Francois M.
    Morozov, Alex
    Navaie, Will
    Pearson, Sarah
    Shaaban, Abeer
    Wydenbach, Kirsty
    Kearns, Pamela R.
    Abouzeid, Christiane
    Ahmed, Rubina
    Bailey, Sue
    Blewett, Catherine
    Campbell, Helen
    Cerone, Maria Antonietta
    Clack, Glen
    Cook, Natalie
    Ghiorghiu, Serban
    Halford, Sarah
    Johnston, Andrew
    Kaplan, Rick
    Lawson, Anna
    Lowe, Emma
    Mathews, Jacqueline
    Mirabile, Ilaria
    Osipenko, Leeza
    Patel, Dipak
    Potter, Claire
    Regan, Aoife
    Ricamara, Marivic
    Ringrose, Carly
    Rodger, Joanne
    Sandhu, Gurcharan K.
    Schiavone, Francesca
    Silvester, Julie
    Sydes, Matthew R.
    Weller, Charles
    Yiangou, Angeliki
    [J]. BRITISH JOURNAL OF CANCER, 2020, 122 (04) : 473 - 482
  • [7] Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer
    Brown, Louise C.
    Graham, Janet
    Fisher, David
    Adams, Richard
    Seligmann, Jenny
    Seymour, Matthew
    Kaplan, Richard
    Yates, Emma
    Parmar, Mahesh
    Richman, Susan D.
    Quirke, Philip
    Butler, Rachel
    Shiu, Kaikeen
    Middleton, Gary
    Samuel, Leslie
    Wilson, Richard H.
    Maughan, Timothy S.
    [J]. CLINICAL TRIALS, 2022, 19 (02) : 146 - 157
  • [8] Adding new experimental arms to randomised clinical trials: Impact on error rates
    Choodari-Oskooei, Babak
    Bratton, Daniel J.
    Gannon, Melissa R.
    Meade, Angela M.
    Sydes, Matthew R.
    Parmar, Mahesh K. B.
    [J]. CLINICAL TRIALS, 2020, 17 (03) : 273 - 284
  • [9] The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
    Dimairo, Munyaradzi
    Pallmann, Philip
    Wason, James
    Todd, Susan
    Jaki, Thomas
    Julious, Steven A.
    Mander, Adrian P.
    Weir, Christopher J.
    Koenig, Franz
    Walton, Marc K.
    Nicholl, Jon P.
    Coates, Elizabeth
    Biggs, Katie
    Hamasaki, Toshimitsu
    Proschan, Michael A.
    Scott, John A.
    Ando, Yuki
    Hind, Daniel
    Altman, Douglas G.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 369
  • [10] Platform Trials - Beware the Noncomparable Control Group
    Dodd, Lori E.
    Freidlin, Boris
    Korn, Edward L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) : 1572 - 1573